07th week of 2013 patent applcation highlights part 34 |
Patent application number | Title | Published |
20130039824 | METHOD OF PRODUCING SODA ASH AND CALCIUM CHLORIDE - The method of producing soda ash and calcium chloride provides an environmentally friendly method of producing soda ash and calcium chloride without the production of waste and hazardous byproducts. The method of producing soda ash and calcium chloride is initiated with a volume of brine, which is ammoniated with gaseous ammonia to form ammoniated brine. Limestone is heated to produce calcium oxide and carbon dioxide. The ammoniated brine is reacted with the carbon dioxide to produce sodium bicarbonate, ammonium chloride and a brine effluent. The sodium bicarbonate is then calcined and decomposed to produce soda ash and gaseous carbon dioxide. The calcium oxide is reacted with the ammonium chloride to produce calcium chloride, water and ammonia. The ammonia is recycled to be used in the initial step of ammoniating the brine. The water and the brine effluent are also recycled and used to provide the brine in the initial step. | 2013-02-14 |
20130039825 | BARIUM CONTAINING GRANULES FOR SORPTION APPLICATIONS - A method for preparation of a getter material on the basis of intermetallic compounds of barium is described. The method comprises preparing a melt of a ternary mixture containing barium, metal and sodium; directionally solidifying the melt to produce a textured ingot; granulating the textured ingot, thereby obtaining granules having open-ended voids extending therethrough; and evaporating the sodium from the granules by applying a thermovacuum treatment to the granules. The textured ingot comprises a getter body made of intermetallic compounds of barium; and open-ended voids within the getter body. | 2013-02-14 |
20130039826 | METHODS FOR REMOVAL OF MERCURY FROM FLUE GAS - Methods and systems for reducing mercury emissions are provided herein. The methods, generally, include the steps of burning a heavy metal containing fuel source and introducing sorbent materials and introducing one or more halogen compounds into the combustion chamber and/or exhaust stream to remove the heavy metal. | 2013-02-14 |
20130039827 | Selective Catalytic NOx Reduction Process and Control System - A process and an apparatus enhance urea utilization for selective catalytic reduction (SCR) of NO | 2013-02-14 |
20130039828 | CATALYST STRUCTURES - A catalyst structure suitable for use in an ammonia oxidation process is described including a plurality of shaped catalyst units supported on one or more members in a spaced relationship that allows the structure to flex. | 2013-02-14 |
20130039829 | ACID GAS RECOVERY UTILIZING ORGANIC ACID SALTED DIAMINE - A process for the capture of sulfur dioxide from a gaseous stream utilizing a regenerable diamine absorbent comprising a diamine and a weak organic acid. | 2013-02-14 |
20130039830 | METHOD FOR REMOVING IMPURITIES FROM SILICON - A method for removing impurities from silicon includes A) providing metallic silicon having impurities, B) mixing the metallic silicon with at least one halogenated polysilane of Formula SiX | 2013-02-14 |
20130039831 | METHOD OF PREPARING A HYDRIDOHALOSILANE COMPOUND - A method of preparing a hydridohalosilane compound comprises treating a preformed metal silicide with a mixture comprising hydrogen gas and a silicon tetrahalide to prepare the hydridohalosilane compound. | 2013-02-14 |
20130039832 | METHOD OF PRODUCING SILICON CARBIDE - A method of producing silicon carbide is provided. The method includes heating a cured product of a curable silicone composition in a non-oxidizing atmosphere at a temperature exceeding 1,500° C. but not more than 2,600° C. The method is capable of producing high-purity silicon carbide simply and at a high degree of productivity, and is capable of simply producing a silicon carbide molded item having a desired shape and dimensions. | 2013-02-14 |
20130039833 | SYSTEMS AND METHODS FOR PRODUCING AMMONIA FERTILIZER - Provided herein are systems and methods for producing ammonia fertilizer for culturing algae and aquaculture. The integrated systems provided herein can be installed on a hydrocarbon production platform and encompasses equipment and processes for generating electricity, preparation of an aqueous electrolyte, hydrogen generation by electrolysis, catalysis of ammonia formation, collection of ammonia, and optionally a nitrogen generator, and a plurality of subsystems for algae culture, and aquaculture. | 2013-02-14 |
20130039834 | METHOD FOR PRODUCING AMMONIA - A method produces ammonia by reacting N | 2013-02-14 |
20130039835 | Hydrogen and Nitrogen Recovery from Ammonia Purge Gas - An ammonia plant is disclosed, where ammonia purge gas ( | 2013-02-14 |
20130039836 | Heterogeneous, Composite, Carbonaceous Catalyst System and Methods that use Catalytically Active Gold - Heterogeneous catalyst systems, methods of making these systems, and methods of using these systems, wherein catalytically active gold is deposited onto composite support media. The composite support media is formed by providing nanoporous material on at least a portion of the surfaces of carbonaceous host material. In representative embodiments, relatively fine, nanoporous guest particles are coated or otherwise provided on surfaces of relatively coarser activated carbon particles. Catalytically active gold may be deposited onto one or both of the guest or host materials either before or after the guest and host materials are combined to from the composite host material. PVD is the preferred catalyst system of depositing gold. | 2013-02-14 |
20130039837 | Method for the Continuous Recovery of Carbon Dioxide from Acidified Seawater - A method for recovering carbon dioxide from acidified seawater using a membrane contactor and passing seawater with a pH less than or equal to 6 over the outside of a hollow fiber membrane tube while applying vacuum or a hydrogen sweep gas to the inside of the hollow fiber membrane tube, wherein up to 92% of the re-equilibrated [CO | 2013-02-14 |
20130039838 | SYSTEMS AND METHODS FOR PRODUCTION OF NANOSTRUCTURES USING A PLASMA GENERATOR - The present disclosure provides systems and methods for production of nanostructures using a plasma generator. In an embodiment, a system for use with a reactor for synthesis of nanostructures may include a chamber defining a pathway for directing a fluid mixture for the synthesis of nanostructures through the chamber. The system may further include one or more heating zones disposed along the chamber to provide a temperature gradient in the chamber to form catalyst particles upon which nanostructures can be generated from the components of the fluid mixture. The system may also include a plasma generator for generating a plasma flame in a conduit through which the fluid mixture may be passed to decompose a carbon source in the fluid mixture into its constituent atoms before proceeding into the reactor for formation of nanostructures. | 2013-02-14 |
20130039839 | PRODUCTION OF CARBON NANOTUBES - The invention relates to a novel process for the production of catalysts for the production of carbon nanotubes in agglomerated form, which are characterised by a low bulk density. This invention likewise provides the catalysts, their use in the production of carbon nanotubes in high catalyst-specific yields, and the carbon nanotubes produced by this process. | 2013-02-14 |
20130039840 | CARBON BLACK REACTOR - The present invention discloses a reactor ( | 2013-02-14 |
20130039841 | Method For Carbon Black Production Using Preheated Feedstock And Apparatus For Same - Methods for production of carbon black using high temperature feedstock at temperatures exceeding about 300° C. with fouling control are provided. An apparatus for production of carbon black according to these methods also is provided. | 2013-02-14 |
20130039842 | METHOD FOR PRODUCING CHLORINE USING FIXED BED REACTOR - The present invention is a method of producing chlorine where it is possible to inhibit the degradation of a catalyst, the corrosion of an apparatus material caused by raw material hydrogen chloride and/or generated chlorine, and a runaway reaction by preventing hot spot generation in a catalyst layer, wherein the method includes a reaction of oxidizing hydrogen chloride in a gas containing the hydrogen chloride using a gas containing oxygen by a fixed bed reactor having a reaction region composed of a catalyst layer and the catalyst layer has an effective thermal conductivity of 0.30 W/(Km) or more, based on a catalyst-filled layer, measured at 350° C. in an air atmosphere. | 2013-02-14 |
20130039843 | APPARATUS FOR FORMING METAL OXIDE FILM, METHOD FOR FORMING METAL OXIDE FILM, AND METAL OXIDE FILM - A film forming apparatus ( | 2013-02-14 |
20130039844 | PROCESS FOR MAKING TITANIUM COMPOUNDS - Disclosed is a process for the preparation of Li | 2013-02-14 |
20130039845 | Method For Producing Hydrogen - A method for production of hydrogen. In the method, an aqueous solution of a chalcogenoxanthylium compound, a catalyst and sacrificial electron donor are exposed to electromagnetic radiation with a wavelength of from 400 nm to 850 nm. Exposure of the aqueous solution to the electromagnetic radiation results in production of hydrogen. Such a method can be used, for example, in dye-sensitized solar cell. | 2013-02-14 |
20130039846 | METHOD FOR PRODUCING HYDROGEN - The invention provides a method for producing hydrogen capable of easily obtaining hydrogen from water under lower temperature and pressure conditions as compared with a conventional method. | 2013-02-14 |
20130039847 | LIPOSOMES FOR PULMONARY ADMINISTRATION - The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 μm and 5 μm, preferably between 0.2 μm and 2.0 μm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 μm and 6 μm, preferably between 1.5 μm and 5 μm, in particular preferably between 2 μm and 4.5 μm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37° C., preferably greater than 45° C., in particular preferably greater than 50° C. | 2013-02-14 |
20130039848 | FLUORESCENT SILICA-BASED NANOPARTICLES - The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques. | 2013-02-14 |
20130039849 | ADENOCARCINOMA SPECIFIC ANTIBODY SAM-6, AND USES THEREOF - The present invention features a polypeptide, such as an antibody produced by the hybridoma SAM-6 and its use in the treatment and diagnosis of neoplasms. | 2013-02-14 |
20130039850 | HETEROLOGOUS ANTIBODIES WHICH BIND HUMAN CD4 - The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies. | 2013-02-14 |
20130039851 | Stabilizing Alkylglycoside Compositions and Methods Thereof - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof. | 2013-02-14 |
20130039852 | METHODS OF TARGETING CELLS FOR DIAGNOSIS AND THERAPY - Methods of making bispecific binding complexes and nanopolymers coupled to detection and/or therapeutic agents are disclosed. Also disclosed are methods of using such bispecific binding complexes and nanopolymers for detecting and treating cells. | 2013-02-14 |
20130039853 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS - Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia. | 2013-02-14 |
20130039854 | MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER - A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity. | 2013-02-14 |
20130039855 | APTAMER TO FGF2 AND USE THEREOF - Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like. | 2013-02-14 |
20130039856 | Products and Methods - The present invention concerns medicaments for slowing ageing. The medicaments can include an inhibitor of microbial folate biosynthesis as well as agents capable of reducing folate uptake by an animal. Examples of such medicaments include inhibitors that reduce the activity of an enzyme in the folate biosynthesis pathway, such as sulfonamides including sulfamethoxazole. The invention also concerns a food supplement, additive, functional food, or nutraceutial comprising the inhibitor or agent or composition as discussed above, as well as methods for screening for an agent for use as a medicament for slowing ageing comprising determining whether a test agent inhibits microbial folate biosynthesis, or whether the test agent reduces folate uptake by a non-human animal. | 2013-02-14 |
20130039857 | METHODS OF SUPPRESSING CANCER, INCREASING WEIGHT LOSS AND/OR INCREASING INSULIN SENSITIVITY - The present invention provides methods for determining if an agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity, comprising contacting Fyn and/or LKB1 with the agent and determining if the agent inhibits Fyn kinase activity or inhibits the interaction between Fyn and LKB1, wherein inhibition of Fyn kinase activity or inhibition of the interaction between Fyn and LKB1 by the agent indicates that the agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity. The present invention also provides methods for treating cancer, treating obesity, or increasing insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits Fyn kinase or that inhibits the interaction between Fyn and LKB1. | 2013-02-14 |
20130039858 | NIR MATERIALS AND NANOMATERIALS FOR THERANOSTIC APPLICATIONS - Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and in other embodiments of the invention a dye is coordinate or ionic bound within the metal oxide matrix. A method for preparing the novel covalently bondable modified fluorescent dyes is presented. A method to prepare silica comprising nanoparticles that are 3 to 8 nm in diameter is presented. In some embodiments, the fluorescent dye comprising metal oxide nanoparticles are further decorated with functionality for use as multimodal in vitro or in vivo imaging agents. In other embodiments of the invention, the fluorescent dye comprising metal oxide nanoparticles provide therapeutic activity and incorporated therapeutic temperature monitoring. | 2013-02-14 |
20130039859 | PASSIVATED NANOPARTICLES - Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein. | 2013-02-14 |
20130039860 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: | 2013-02-14 |
20130039861 | Dye Conjugated Peptides for Fluorescent Imaging - The present application discloses compositions and methods of use of dye conjugated peptides for fluorescent detection, diagnosis and/or imaging. In preferred embodiments, the compositions comprise a DNL complex comprising an anti-hapten antibody or antigen-binding fragment thereof conjugated to an AD moiety and a DDD moiety conjugated to an antibody or antigen-binding fragment thereof that binds to the target antigen, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the DNL complex. More preferably, the compositions comprise a targetable construct comprising at least one hapten and a fluorescent probe. Binding of the DNL complex to the target antigen and of the hapten on the targetable construct to the DNL complex results in fluorescent labeling of the target antigen. Most preferably, fluorescent imaging is of use in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures for detection of diseased tissues. | 2013-02-14 |
20130039862 | COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD - The invention relates to novel compounds of dibenzylidene sorbitol ester type corresponding to the following formulae (I) and (II): | 2013-02-14 |
20130039863 | METHODS OF CONTROLLING THE BREEDING BEHAVIOR OF BUTTERFLIES - Methods of controlling the feeding and/or breeding behavior of a target insect are disclosed in which a host plant is provided a substantial distance from a plant of interest, chemical attractant that induces the target insect to lay eggs on the host plant is applied to the host plant, application of the chemical attractant to the host plant is repeated as required to induce residual target-insect populations to lay eggs on the host plant, and wherein the behavior is controlled when a substantial number of off-spring belonging to subsequent generations themselves mature and display a preference for laying eggs on the same type of host plant on which they were reared without further application of the chemical attractant is provided. Also disclosed are methods of deterring target insect feeding and breeding on plants of interest by applying toxic plant extract to the plants of interest. | 2013-02-14 |
20130039864 | Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof - The disclosure relates to a non-intravenous dosage for administration of a liquid biologically active agent. The dosage form contains a solid formulation of the liquid biologically active agent, e.g. propofol, in intimate association with at least one stabilizing agent, e.g. an amphiphilic polymer or surfactant. A liquid biologically active agent is converted to a solid product, e.g. a powder, that can be easily incorporated into a number of different non-intravenous dosage forms. Upon hydration, a nanodispersion or micelle loaded with the active agent is formed. The dosage form can provide a non-intravenous route of administration for active agents that are typically only administered intravenously. Methods, uses, kits and commercial packages related to the non-intravenous dosage form are also disclosed. | 2013-02-14 |
20130039865 | ORAL CARE COMPOSITIONS AND METHODS - Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition. | 2013-02-14 |
20130039866 | COMPOSITION FOR THE PROPHYLAXIS OF CANDIDIASIS - The invention solves the problem of the practical realization of an effective prophylactic composition which uses available and safe components and which can be recommended for preventing the growth of candidiasis of the skin and/or mucous membranes in humans in the following risk group: sufferers of diabetes mellitus, people with blood diseases, immune deficiency and other serious pathologies, patents after a course of hormone therapy, antibiotic treatment or chemotherapy, as well as for babies and pregnant women; and for people using tooth implants. The composition for the prophylaxis of candidiasis comprises active components, with the active components used being xylitol in a quantity of 0.3-20.0% by mass and sodium or potassium alginate or a mixture thereof in a quantity of 0.01-2.0% by mass, as well as inert components. | 2013-02-14 |
20130039867 | Oral Care Composition Comprising Stannous and Nitrate Ions - An oral care composition comprising a) an aqueous phase; b) stannous ions solvated in the aqueous phase; c) nitrates solvated in the aqueous phase; wherein the total content of said nitrates is such that the molar amount of nitrogen in the aqueous phase, measurable as nitrate, is less than 2 times the molar amount of solvated stannous ions; and d) a flavour substance, which is preferably solvated, dispersed or emulgated in the aqueous phase. Disclosed are also containers containing the composition; and processes and uses for stabilising stannous ions against oxidation, using nitrates. | 2013-02-14 |
20130039868 | Dentifrice Composition - A teeth whitening dentifrice that enhances the shades of teeth with only a short application on the teeth. The dentifrice disrupts the surface tension between the teeth and the stains to provide with the aid of commonly known mechanical brushing and rising methods. 1 to 3 shades of whiter teeth. The toothpaste combines a non-polar solvent, a polar solvent, and a surfactant. An emulsion creates electrostatic interactions with the polar solvent and a reverse micelle to create a hydrophobic compound, which combines with the non-polar solvent to create a non-polar environment on the teeth. The polar solvent's strong electrostatic interactions in reverse micelles accelerate the removal of soluble material. The non-polar environment bonds with insoluble materials, such as extrinsic stains, to disrupt the surface tension between the teeth and the stain. Bleaching agents, thickeners, polishing agents, and other enhancers are mixed to the toothpaste to provide additional functions and characteristics. | 2013-02-14 |
20130039869 | ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM - Regimen for the treatment of rosacea include the application of an anti-redness composition to at least a portion of the cleansed area of skin afflicted with rosacea. The regimen may include the application of one or more of a polymetal complex, a composition containing metronidazole, and/or a protective composition. Kits containing components useful in performing such regimens are also described. | 2013-02-14 |
20130039870 | Cosmetic Or Dermatological Preparations With A Content Of One Or More Thiazole Derivates - Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula | 2013-02-14 |
20130039871 | AQUEOUS COMPOSITION CONTAINED IN CONTAINER - Provided is an aqueous composition contained in a container, where water evaporation of the aqueous composition contained in a container is inhibited, and thereby the contents are prevented from solidifying or changing in properties. As a result, excellent long-term stability is obtained, and even when the container is a spray container or a pump container, the contents adhering to the discharge opening of the container is inhibited from drying, and thereby clogging can be prevented. The aqueous composition contained in a container contains the following components (A), (B), and (C): (A) a polyoxyethylene alkyl or alkenyl ether having an alkyl or alkenyl group having 20 to 24 carbon atoms and an average molar number of ethylene oxide added of 1.5 to 4, (B) a water-soluble polymer, and (C) water. | 2013-02-14 |
20130039872 | ESTER PREPARATION WITH AFTER-TREATMENT - The present invention relates to a process for the preparation of an ester in a reactor, a device, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the invention or the thermoplastic composition according to the invention, a process for the production of a packed product, a process for the production of an at least partly coated object, and uses of the esters according to the invention as an additive in various compositions. | 2013-02-14 |
20130039873 | HAIR AND SKIN CONDITIONING COMPOSITIONS - Compositions for providing hair and skin care benefits, such as smoothing, anti-static control, color protection, frizz control and moisturization are disclosed. The compositions maintain clarity, show no separation upon standing, and remain flowable liquids at room temperature. The compositions comprise a silicone or hydrocarbon component having a viscosity of from about 2,500 to about 600,000 cSt at 25° C. (such as dimethicone gum or hydrogenated polydecene), together with a carrier fluid having a viscosity less than about 100 cSt at 25° C. and a flash point greater than about 85° C. (such as caprylyl methicone, isodecyl neopentanoate, or hydrogenated polyisobutene (250)). Hair care compositions, such as shampoos and conditioners containing those combinations, as well as the method of conditioning hair utilizing those compositions is also disclosed. The compositions can be applied directly to the hair (i.e., “neat”) or via a conventional hair treatment composition, such as a shampoo or a conditioner. Skin care compositions and methods are also disclosed. | 2013-02-14 |
20130039874 | MASCARA CONTAINING AN AQUEOUS DISPERSION OF POLYURETHANE AND AN ACRYLIC FILM FORMER - The invention relates to a composition comprising at least one aqueous polyurethane dispersion and at least one acrylic film forming agent. | 2013-02-14 |
20130039875 | SHAMPOO CONTAINING A DENDRITIC MACROMOLECULE AND A GEL NETWORK - A hair care composition comprising: i) a cleaning phase comprising a cleansing anionic surfactant which is a salt and comprises an alkyl group with from 8 to 14 carbons; ii) an aqueous conditioning gel network having no overall charge or is anionic, the gel network comprising: (a) fatty material; (b) a gel network anionic surfactant comprising an alkyl group with from 16 to 30 carbons; (c) cationic surfactant; and iii) a dendritic macromolecule. In particular, the composition is a shampoo. A preferred cleansing anionic surfactant is sodium laureth sulfate, fatty material is cetostearyl alcohol, gel network anionic surfactant is sodium cetylstearyl sulfate, cationic surfactant is cetyl or behenyl trimethylammonium chloride and dendritic macromolecule is a polyhydric polyester alcohol or hyperbranched polyol. | 2013-02-14 |
20130039876 | Perfume Compositions - Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients in the aggregate percentage of Group B ingredients present must be at least equal to the expression (2*/10−A %) where A % is the total percentage of Group A ingredients in the composition. | 2013-02-14 |
20130039877 | Perfume Compositions - Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients in the aggregate percentage of Group B ingredients present must be at least equal to the expression (2*/10-A %) where A % is the total percentage of Group A ingredients in the composition. | 2013-02-14 |
20130039878 | TRIPLE CROSS-LINKED COLLAGEN, METHOD OF MANUFACTURING THE SAME, AND USE THEREOF - The present invention relates to a method for manufacturing a triple cross-linked collagen, which comprises the following steps: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a one cross-linked collagen; mixing the first cross-linked collagen with a second cross-linking agent to form a second cross-linked collagen; and mixing the second cross-linked collagen with a third cross-linking agent to form a triple cross-linked collagen, wherein each of the first cross-linking agent, the second cross-linking agent, and the third cross-linking agent is selected from the group consisting of an aldehyde cross-linking agent, an imine cross-linking agent, and an epoxide cross-linking agent. In addition, the first cross-linking agent is different form the second cross-linking agent, and the third cross-linking agent is different form the first cross-linking agent and the second cross-linking agent. | 2013-02-14 |
20130039879 | Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 2013-02-14 |
20130039880 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2013-02-14 |
20130039881 | COMBINATION FOR THE TREATMENT OF RADIATION- OR CHEMOTHERAPY-INDUCED MUCOSITIS - The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of mucositis induced by radiation or chemotherapy. | 2013-02-14 |
20130039882 | METHOD TO MITIGATE INJURY FROM RADIATION EXPOSURE - Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal. | 2013-02-14 |
20130039883 | METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF DEATH RECEPTOR LIGANDS IN CANCER TREATMENT - Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or a withanolide (II). Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with a compound described herein, for example, a cucurbitacin (I) or a withanolide (II) and also contacting the cancer cells with a death receptor ligand, whereby apoptosis is induced in the cancer cells. | 2013-02-14 |
20130039884 | COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES - The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 2013-02-14 |
20130039885 | LEUKOTOXIN E/D AS A NEW ANTI-INFLAMMATORY AGENT AND MICROBICIDE - The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating | 2013-02-14 |
20130039886 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 2013-02-14 |
20130039887 | Methods of Identifying and Using Anti-Viral Compounds - Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells. | 2013-02-14 |
20130039888 | PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS - The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. | 2013-02-14 |
20130039889 | RECOMBINANT MICROORGANISMS - The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof. | 2013-02-14 |
20130039890 | TREATMENT OF TUMORS WITH GENETICALLY ENGINEERED HERPES VIRUS - Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus. | 2013-02-14 |
20130039891 | POXVIRAL ONCOLYTIC VECTORS - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | 2013-02-14 |
20130039892 | ADHERENT STROMAL CELLS DERIVED FROM PLANCENTAS OF MULTIPLE DONORS AND USES THEREOF - Pharmaceutical compositions comprising adherent stromal cells (ASCs) are provided. The ASCs are obtained from at least two donors. Articles of manufacture comprising the pharmaceutical compositions together with a delivery device for administering the ASCs to a subject are also provided. Also provided are methods of treating various diseases and conditions that are treatable by administering ASCs to a subject in need of treatment. | 2013-02-14 |
20130039893 | ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM - The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. | 2013-02-14 |
20130039894 | Polypeptides and Use Thereof for Treatment of Traumatic or Degenerative Neuronal Injury - The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of damage of the peripheral or central nervous system. | 2013-02-14 |
20130039895 | MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS - The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively. | 2013-02-14 |
20130039896 | PHARMACEUTICAL KITS COMPRISING MESENCHYMAL STEM CELLS - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 2013-02-14 |
20130039897 | COMPOSITIONS AND METHODS FOR REGULATING NEUTROPHIL MOVEMENT AND NEUTROPHIL NUMBERS IN A BODY REGION - The disclosure relates to compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a | 2013-02-14 |
20130039898 | COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOF - Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer. | 2013-02-14 |
20130039899 | METHODS AND DEVICES FOR APPLYING TISSUE SEALANTS AND ADHESIVES - Methods of application and devices thereof for tissue adhesives. The adhesives comprise a plurality of components which are provided separately but which are mixed together to form the adhesive. At least one component is a crosslinkable protein solution and at least one other component is a crosslinking material solution. The devices preferably include a mixing unit, which may include dynamic mixing elements, static mixing elements, or a combination of the two. | 2013-02-14 |
20130039900 | COMPOSITIONS AND METHODS FOR ALTERING COCAINE ESTERASE ACTIVITY - The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction. | 2013-02-14 |
20130039901 | Treatment of Pompe's Disease - The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient. | 2013-02-14 |
20130039902 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire | 2013-02-14 |
20130039903 | ECZEMA TREATMENT - A use of a composition including lactoferrin and/or immunoglobulin for minimizing the severity of one or more symptoms associated with eczema. | 2013-02-14 |
20130039904 | GAMBOGIC ACID CYCLIZATION ANALOGUES, THEIR PREPARATION METHOD AND APPLICATION THEREOF - The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: | 2013-02-14 |
20130039905 | Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease - The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburg's acute M S, Balós's concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO). | 2013-02-14 |
20130039906 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE - Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R | 2013-02-14 |
20130039907 | METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW - The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders. | 2013-02-14 |
20130039908 | PROGNOSTIC MARKERS AND METHODS FOR PROSTATE CANCER - The present invention relates to methods and compositions for the diagnosis, prognosis and treatment of neoplastic disorders. Some embodiments include methods, compositions, and kits for the prognosis and treatment of prostate cancer. | 2013-02-14 |
20130039909 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 2013-02-14 |
20130039910 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 2013-02-14 |
20130039911 | Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins - The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells. | 2013-02-14 |
20130039912 | ROBO1-FC FUSION PROTEIN AND USE THEREOF FOR TREATING TUMOURS - The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient. | 2013-02-14 |
20130039913 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. | 2013-02-14 |
20130039914 | NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein. | 2013-02-14 |
20130039915 | SIGLEC 15 ANTIBODIES IN TREATING BONE LOSS-RELATED DISEASE - Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed. | 2013-02-14 |
20130039916 | ENGINEERED ANTI-IL-23p19 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2013-02-14 |
20130039917 | DIAGNOSTIC AND THERAPEUTIC TARGET - The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell. | 2013-02-14 |
20130039918 | Pharmaceutical Composition Using Connective-tissue Growth Factor - This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Ca | 2013-02-14 |
20130039919 | NOVEL PLASMINOGEN RECEPTOR, POLYPEPTIDES AND ANTIBODIES THEREOF - The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-R | 2013-02-14 |
20130039920 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody. | 2013-02-14 |
20130039921 | Treatment of Inflammatory Skin Disease and Psychiatric Conditions - The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment. | 2013-02-14 |
20130039922 | ANTIBODIES THAT INHIBIT METALLOPROTEINS - The present application relates to antibodies which recognize [2 (2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed. | 2013-02-14 |
20130039923 | ANTI-HUMAN INTERLEUKIN-20 ANTIBODIES - Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders. | 2013-02-14 |